Iovance Biotherp Stock Price, News & Analysis

Iovance Biotherapeutics has initiated the IOV-GM1-201 trial, marking a key step in developing its genetically modified TIL therapy, IOV-4001, targeting metastatic non-small cell lung cancer and advanced melanoma. The trial is a first-in-human study assessing the therapy's safety and efficacy. The innovative approach involves TALEN^® gene editing to inactivate PD-1, aiming to enhance anti-tumor activity. The trial is currently enrolling participants, indicating potential advancements in cancer treatment options.

Iovance Biotherapeutics announced oral and poster presentations for the C-144-01 trial at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting on November 10, 2022. The presentations cover the lifileucel TIL cell monotherapy for advanced melanoma and a Phase 1/2 study of TALEN-mediated PD-1–inactivated TILs in melanoma and NSCLC. A conference call will discuss the pooled analysis of the trial's cohorts. With a focus on advancing TIL therapies, Iovance aims to innovate cancer treatment.

Iovance Biotherapeutics, a late-stage biotechnology company focused on cancer immunotherapy, plans to present at several key conferences in September. These include the Wells Fargo Healthcare Conference on September 7, HC Wainwright Annual Global Investment Conference starting September 12, Baird Global Healthcare Conference on September 13, and the Cantor Oncology Conference on September 28. The events will feature discussions about their lead product candidate, lifileucel, which aims to be the first approved one-time cell therapy for solid tumors. Webcasts will be available online.

Iovance Biotherapeutics (NASDAQ: IOVA) announced the publication of clinical data and trial designs for its tumor infiltrating lymphocyte (TIL) therapies at the ESMO Congress 2022 in Paris, from September 9-13, 2022. Two key abstracts were presented: Abstract #844P on the efficacy of lifileucel in advanced melanoma and Abstract #883TiP detailing a study on PD-1 inactivated TIL. These advances are part of Iovance's commitment to developing TIL therapies aimed at transforming cancer treatment.

Iovance Biotherapeutics has initiated a rolling Biologics License Application (BLA) submission for lifileucel, a T cell-based therapy targeting advanced melanoma. This marks a significant step toward offering the first individualized, one-time cell treatment for patients with limited options. With no current FDA-approved therapies in this setting, Iovance's submission is anticipated to be completed by Q4 2022. The BLA is bolstered by positive clinical data from the C-144-01 trial, and the FDA has designated lifileucel as a regenerative medicine advanced therapy.

Iovance Biotherapeutics (NASDAQ: IOVA) reported its second quarter and first half 2022 results, highlighting a net loss of $99.3 million, or $0.63 per share, compared to $81.4 million, or $0.53 per share, in Q2 2021. The company is on track to submit its first Biologics License Application (BLA) for lifileucel in metastatic melanoma, having received favorable FDA feedback. Cash reserves stand at $430.9 million, sufficient to fund operations into 2024. Increased expenses in R&D and G&A are attributed to team growth and pre-commercial activities, reflecting ongoing development in their TIL therapy pipeline.

Iovance Biotherapeutics (NASDAQ: IOVA) will release its second quarter financial results on August 4, 2022. The company is focused on developing innovative T cell-based cancer therapies, particularly its lead product candidate, lifileucel, for metastatic melanoma. This therapy aims to be the first approved one-time cell treatment for solid tumors. Management will conduct a conference call to discuss the results, with listeners able to participate via registration. Further information is accessible on Iovance's investor relations website.

Iovance Biotherapeutics has granted inducement stock options totaling 39,400 shares to 15 new non-executive employees as of July 21, 2022. These options, part of the 2021 Inducement Plan, have an exercise price of $12.52, matching the closing stock price on the grant date. The options will vest over three years, with one-third vesting on the first anniversary of employment and the remainder in eight quarterly installments, contingent on continued employment. Iovance aims to lead in T cell-based therapies for cancer, particularly with lifileucel for metastatic melanoma.

Iovance Biotherapeutics approved the grant of 68,225 inducement stock options to 14 new non-executive employees on June 16, 2022. These options were issued under the 2021 Inducement Plan with an exercise price of $8.13, equal to the stock's closing price on the grant date. The options will vest over three years, with one-third vesting on the first anniversary of each employee's start date. This initiative aligns with Iovance's strategy to attract talent in the competitive biotechnology sector.